227 related articles for article (PubMed ID: 34680503)
1. Clinically Translatable Approaches of Inhibiting TGF-β to Target Cancer Stem Cells in TNBC.
Sulaiman A; McGarry S; Chilumula SC; Kandunuri R; Vinod V
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680503
[TBL] [Abstract][Full Text] [Related]
2. At the Intersection of Cardiology and Oncology: TGFβ as a Clinically Translatable Therapy for TNBC Treatment and as a Major Regulator of Post-Chemotherapy Cardiomyopathy.
Sulaiman A; Chambers J; Chilumula SC; Vinod V; Kandunuri R; McGarry S; Kim S
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326728
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
[TBL] [Abstract][Full Text] [Related]
4. CSCs in Breast Cancer-One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs.
Sulaiman A; McGarry S; Han X; Liu S; Wang L
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31394796
[TBL] [Abstract][Full Text] [Related]
5. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
6. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
[TBL] [Abstract][Full Text] [Related]
7. Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance.
Jalalirad M; Haddad TC; Salisbury JL; Radisky D; Zhang M; Schroeder M; Tuma A; Leof E; Carter JM; Degnim AC; Boughey JC; Sarkaria J; Yu J; Wang L; Liu MC; Zammataro L; Malatino L; Galanis E; Ingle JN; Goetz MP; D'Assoro AB
Oncogene; 2021 Apr; 40(14):2509-2523. PubMed ID: 33674749
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
Sulaiman A; McGarry S; Lam KM; El-Sahli S; Chambers J; Kaczmarek S; Li L; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Liu S; Xie Y; Gadde S; Li X; Wang L
Cell Death Dis; 2018 Jul; 9(8):815. PubMed ID: 30050079
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
10. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
[TBL] [Abstract][Full Text] [Related]
11. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
Bhola NE; Balko JM; Dugger TC; Kuba MG; Sánchez V; Sanders M; Stanford J; Cook RS; Arteaga CL
J Clin Invest; 2013 Mar; 123(3):1348-58. PubMed ID: 23391723
[TBL] [Abstract][Full Text] [Related]
12. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy.
Sulaiman A; McGarry S; El-Sahli S; Li L; Chambers J; Phan A; Côté M; Cron GO; Alain T; Le Y; Lee SH; Liu S; Figeys D; Gadde S; Wang L
Mol Cancer Ther; 2019 Oct; 18(10):1755-1764. PubMed ID: 31308079
[TBL] [Abstract][Full Text] [Related]
14. Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalence.
Petrella PE; Chen JW; Ravelo GO; Cosgrove BD
bioRxiv; 2024 Apr; ():. PubMed ID: 38746322
[TBL] [Abstract][Full Text] [Related]
15. The miR-124-3p/Neuropilin-1 Axis Contributes to the Proliferation and Metastasis of Triple-Negative Breast Cancer Cells and Co-Activates the TGF-β Pathway.
Zhang J; Zhang X; Li Z; Wang Q; Shi Y; Jiang X; Sun X
Front Oncol; 2021; 11():654672. PubMed ID: 33912463
[TBL] [Abstract][Full Text] [Related]
16. Isotoosendanin exerts inhibition on triple-negative breast cancer through abrogating TGF-
Zhang J; Zhang Z; Huang Z; Li M; Yang F; Wu Z; Guo Q; Mei X; Lu B; Wang C; Wang Z; Ji L
Acta Pharm Sin B; 2023 Jul; 13(7):2990-3007. PubMed ID: 37521871
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review to Clarify the Prognostic Values of CD44 and CD44
Abdoli Shadbad M; Hosseinkhani N; Asadzadeh Z; Derakhshani A; Karim Ahangar N; Hemmat N; Lotfinejad P; Brunetti O; Silvestris N; Baradaran B
Front Oncol; 2021; 11():689839. PubMed ID: 34434894
[TBL] [Abstract][Full Text] [Related]
18. Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells.
Sulaiman A; McGarry S; Chambers J; Al-Kadi E; Phan A; Li L; Mediratta K; Dimitroulakos J; Addison C; Li X; Wang L
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806648
[TBL] [Abstract][Full Text] [Related]
19. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
20. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
